#bio pharmaceutical companies
Our rules for inclusion on the Top 10 Biopharma list are as follows: you re a biopharma company if more than half of your drug revenues not royalties come from large-molecule drugs and vaccines. It s arbitrary, but it s worked pretty well for the past decade. This year, it means that Roche/Genentech has become the world s #1 biopharma, marking the first change at the top in 10 years.
The rest of this year s list is consistent with the previous year s ranks, which is both a sign of the stability among biopharmas and a sign of the difficulty in commercializing new biologics without a major partner.
Several of the Top 10 are legit takeover targets, but no buyout deal is likely to close before the end of the year, so the biggest opportunity for a change is between the 7 and 8 spots, if Genzyme s production woes cause enough of a revenue drop to allow CSL to slip by.
10th anniversary note: in our first edition, Amgen was tops with biopharma revenues of $3.2 billion. There are now eight companies with revenues higher than that!
Top 10 Biopharmaceutical Companies